1377604-63-1

Usage

Uses

Used in Pharmaceutical Industry:
Velpatasvir-A12 is used as a therapeutic agent for the treatment of chronic hepatitis C virus (HCV) infection. It is highly effective in achieving sustained virologic response, which means the virus is undetectable in the blood after the completion of treatment. This makes it an important addition to the treatment options for HCV infection.
Used in Combination Therapy:
Velpatasvir-A12 is often used in combination with other antiviral drugs to increase its effectiveness. This combination therapy enhances the overall treatment outcome by targeting multiple aspects of the virus's life cycle, leading to a higher rate of sustained virologic response and improved patient outcomes.
Used in Antiviral Drug Development:
As a potent antiviral agent, Velpatasvir-A12 serves as a valuable component in the development of new antiviral drugs and treatment strategies for hepatitis C. Its mechanism of action and high efficacy in inhibiting viral replication make it a promising candidate for further research and development in the field of antiviral therapy.
Used in Patient Care:
Velpatasvir-A12 is used to improve the quality of life for patients suffering from chronic hepatitis C virus infection. Its minimal side effects and well-tolerated nature make it a preferred choice for patients who require long-term antiviral treatment. By effectively controlling the virus and reducing the risk of liver damage, Velpatasvir-A12 contributes to better patient outcomes and overall health.

Upstream product

• 1378391-39-9 (2S,4S)-1-tert-butyl 2-(2-oxo-2-(8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)ethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-42-4 (2S,4S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-43-5 (2R,4R)-1-tert-butyl 2-(2-(9-((2S,5S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)-5-methylpyrrolidine-2-carbonyloxy)-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate 
• 1378391-44-6 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,4,5,11-tetrahydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 50890-96-5 (2R)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid 
• 487048-28-2 (2S,4S)-4-cyano-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 
• 1378388-30-7 (2S,4S)-N-(tert-butyloxycarbonyl)pyrrolidine-2,4-dicarboxylic acid dimethyl ester 
• 1378388-35-2 (3S,5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-pyrrolidine-3-carboxylic acid 
• 1194059-42-1 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(hydroxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378393-23-7 C₁₅H₂₃NO₈ 
• 1378388-37-4 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 1378388-16-9 (2S,4S)-N-(tert-butyloxycarbonyl)-4-(methoxymethyl)-pyrrolidine-2-carboxylic acid 

Downstream Products

• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 

Relevant academic research and scientific papers

Method for preparing NS5A inhibitor-Velpatasvir

The invention discloses a method for preparing an NS5A inhibitor-Velpatasvir, wherein the method mainly comprises the five steps: 1) carrying out docking reaction on reaction initial raw materials VPM1, VPM2 and VPM3 under the catalytic action of alkali to prepare an intermediate VP1; 2) removing amino protecting groups from the intermediate VP1 by using a protecting group removing reagent to prepare an intermediate VP2; 3) carrying out cyclization on the intermediate VP2 and an amine compound to prepare an intermediate VP3; 4) carrying out a reaction on the intermediate VP3 with VPM4 under the action of a condensing agent to prepare an amide compound intermediate VP4; and 5) carrying out oxidation reaction on the intermediate VP4 under the action of an oxidizing agent to prepare Velpatasvir. The preparation process of Velpatasvir has the characteristics of simplified route, simple reaction conditions, enhanced operability and higher product yield, and is more suitable for large-scaleindustrial production.

CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS

The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.